Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus…

Read MorePfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase…

Read MoreMerck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck’s…

Read MoreMerck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic technology. The Canady Robotic AI Surgical System is the world’s first…

Read MoreUSMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

Global Cardiac Holter Monitor Market Size, Trends & Forecast Report 2023-2030 Featuring General Electric, NIHON KOHDEN, Hill-Rom, OSI Systems, Boston Scientific, Koninklijke Philips, and Medtronic – ResearchAndMarkets.com

The “Cardiac Holter Monitor Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” report has been added to ResearchAndMarkets.com’s offering. Global Cardiac Holter Monitor Market is projected to reach US$ 713.5 Million in 2030, growing at a CAGR…

Read MoreGlobal Cardiac Holter Monitor Market Size, Trends & Forecast Report 2023-2030 Featuring General Electric, NIHON KOHDEN, Hill-Rom, OSI Systems, Boston Scientific, Koninklijke Philips, and Medtronic – ResearchAndMarkets.com

Kestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23,…

Read MoreKestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus…

Read MorePfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

CORRECTING and REPLACING Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy

Headline of release should read: Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy (instead of Santa Barbara Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy) of release issued…

Read MoreCORRECTING and REPLACING Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023…

Read MorePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the…

Read MoreEuropean Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata